131 related articles for article (PubMed ID: 37877328)
21. Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis.
Flamée L; Symons R; Degtiarova G; Dresselaers T; Gheysens O; Wuyts W; Van Cleemput J; Bogaert J
Eur Radiol; 2020 Jul; 30(7):3702-3710. PubMed ID: 32166494
[TBL] [Abstract][Full Text] [Related]
22. Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.
Velangi PS; Chen KA; Kazmirczak F; Okasha O; von Wald L; Roukoz H; Farzaneh-Far A; Markowitz J; Nijjar PS; Bhargava M; Perlman D; Akçakaya M; Shenoy C
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1395-1405. PubMed ID: 31954639
[TBL] [Abstract][Full Text] [Related]
23. Localization of myocardial FDG uptake for prognostic risk stratification in corticosteroid-naïve cardiac sarcoidosis.
Bekki M; Tahara N; Tahara A; Sugiyama Y; Maeda-Ogata S; Honda A; Igata S; Enomoto M; Kakuma T; Kaida H; Abe T; Fukumoto Y
J Nucl Cardiol; 2022 Oct; 29(5):2132-2144. PubMed ID: 34228338
[TBL] [Abstract][Full Text] [Related]
24. Utility of Updated Japanese Circulation Society Guidelines to Diagnose Isolated Cardiac Sarcoidosis.
Sato K; Kawamatsu N; Yamamoto M; Machino-Ohtsuka T; Ishizu T; Ieda M
J Am Heart Assoc; 2022 Jul; 11(13):e025565. PubMed ID: 35766294
[TBL] [Abstract][Full Text] [Related]
25. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis.
Kouranos V; Tzelepis GE; Rapti A; Mavrogeni S; Aggeli K; Douskou M; Prasad S; Koulouris N; Sfikakis P; Wells A; Gialafos E
JACC Cardiovasc Imaging; 2017 Dec; 10(12):1437-1447. PubMed ID: 28330653
[TBL] [Abstract][Full Text] [Related]
26. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by ¹⁸F- fluorodoexyglucose positron emission tomography?
Mc Ardle BA; Birnie DH; Klein R; de Kemp RA; Leung E; Renaud J; DaSilva J; Wells GA; Beanlands RS; Nery PB
Circ Cardiovasc Imaging; 2013 Sep; 6(5):617-26. PubMed ID: 23884290
[TBL] [Abstract][Full Text] [Related]
27. Prognosis and risk stratification in cardiac sarcoidosis patients with preserved left ventricular ejection fraction.
Chiba T; Nakano M; Hasebe Y; Kimura Y; Fukasawa K; Miki K; Morosawa S; Takanami K; Ota H; Fukuda K; Shimokawa H
J Cardiol; 2020 Jan; 75(1):34-41. PubMed ID: 31277963
[TBL] [Abstract][Full Text] [Related]
28. Utility of new FDG-PET/CT guidelines for diagnosing cardiac sarcoidosis in patients with implanted cardiac pacemakers for atrioventricular block.
Tanabe S; Nakano Y; Ando H; Fujimoto M; Onishi T; Ohashi H; Kuno S; Naito K; Waseda K; Takahashi H; Suzuki Y; Fukuta M; Amano T
Sci Rep; 2024 Apr; 14(1):7825. PubMed ID: 38570621
[TBL] [Abstract][Full Text] [Related]
29. Utility of Cardiac Magnetic Resonance Imaging Versus Cardiac Positron Emission Tomography for Risk Stratification for Ventricular Arrhythmias in Patients With Cardiac Sarcoidosis.
Gowani Z; Habibi M; Okada DR; Smith J; Derakhshan A; Zimmerman SL; Misra S; Gilotra NA; Berger RD; Calkins H; Tandri H; Chrispin J
Am J Cardiol; 2020 Nov; 134():123-129. PubMed ID: 32950203
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of atrial FDG uptake and association with atrial arrhythmias in patients with cardiac sarcoidosis.
Yodogawa K; Fukushima Y; Ando T; Iwasaki YK; Akiyama K; Kumita SI; Azuma A; Seino Y; Shimizu W
Int J Cardiol; 2020 Aug; 313():55-59. PubMed ID: 32320785
[TBL] [Abstract][Full Text] [Related]
31. Incidence and Predictors of Atrial Fibrillation in Cardiac Sarcoidosis: A Multimodality Imaging Study.
Niemelä M; Uusitalo V; Pöyhönen P; Schildt J; Lehtonen J; Kupari M
JACC Cardiovasc Imaging; 2022 Sep; 15(9):1622-1631. PubMed ID: 36075623
[TBL] [Abstract][Full Text] [Related]
32. Hybrid Cardiac Magnetic Resonance/Fluorodeoxyglucose Positron Emission Tomography to Differentiate Active From Chronic Cardiac Sarcoidosis.
Greulich S; Gatidis S; Gräni C; Blankstein R; Glatthaar A; Mezger K; Müller KAL; Castor T; Mahrholdt H; Häntschel M; Hetzel J; Dittmann H; Nikolaou K; Gawaz M; la Fougère C; Krumm P
JACC Cardiovasc Imaging; 2022 Mar; 15(3):445-456. PubMed ID: 34656480
[TBL] [Abstract][Full Text] [Related]
33. Relationship of Mild to Moderate Impairment of Left Ventricular Ejection Fraction With Fatal Ventricular Arrhythmic Events in Cardiac Sarcoidosis.
Akama Y; Fujimoto Y; Matsue Y; Maeda D; Yoshioka K; Dotare T; Sunayama T; Nabeta T; Naruse Y; Kitai T; Taniguchi T; Sato S; Tanaka H; Okumura T; Baba Y; Minamino T
J Am Heart Assoc; 2024 Mar; 13(6):e032047. PubMed ID: 38456399
[TBL] [Abstract][Full Text] [Related]
34. Incremental Prognostic Value of Global Longitudinal Strain and 18F-Fludeoxyglucose Positron Emission Tomography in Patients With Systemic Sarcoidosis.
Sperry BW; Ibrahim A; Negishi K; Negishi T; Patel P; Popović ZB; Culver D; Brunken R; Marwick TH; Tamarappoo B
Am J Cardiol; 2017 May; 119(10):1663-1669. PubMed ID: 28343598
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis.
Baba Y; Kubo T; Kitaoka H; Okawa M; Yamanaka S; Kawada Y; Yamasaki N; Matsumura Y; Furuno T; Sugiura T; Doi YL
Int Heart J; 2012; 53(5):287-92. PubMed ID: 23038089
[TBL] [Abstract][Full Text] [Related]
36. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis.
Vita T; Okada DR; Veillet-Chowdhury M; Bravo PE; Mullins E; Hulten E; Agrawal M; Madan R; Taqueti VR; Steigner M; Skali H; Kwong RY; Stewart GC; Dorbala S; Di Carli MF; Blankstein R
Circ Cardiovasc Imaging; 2018 Jan; 11(1):e007030. PubMed ID: 29335272
[TBL] [Abstract][Full Text] [Related]
37. Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis.
Vis R; Mathijssen H; Keijsers RGM; van de Garde EMW; Veltkamp M; Akdim F; Post MC; Grutters JC
J Nucl Cardiol; 2023 Aug; 30(4):1543-1553. PubMed ID: 36640249
[TBL] [Abstract][Full Text] [Related]
38. FDG-PET in possible cardiac sarcoidosis: Right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events.
Tuominen H; Haarala A; Tikkakoski A; Kähönen M; Nikus K; Sipilä K
J Nucl Cardiol; 2021 Feb; 28(1):199-205. PubMed ID: 30815833
[TBL] [Abstract][Full Text] [Related]
39. Cardiac sarcoidosis outcome differences: A comparison of patients with de novo cardiac versus known extracardiac sarcoidosis at presentation.
Rosen NS; Pavlovic N; Duvall C; Wand AL; Griffin JM; Okada DR; Chrispin J; Tandri H; Mathai SC; Stern B; Pardo CA; Kasper EK; Sharp M; Chen ES; Gilotra NA
Respir Med; 2022 Jul; 198():106864. PubMed ID: 35550245
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis of cardiac sarcoidosis in patients presenting with cardiac arrest or life-threatening arrhythmias.
Hatipoglu S; Gardezi SKM; Azzu A; Baksi J; Alpendurada F; Izgi C; Khattar R; Kouranos V; Wells AU; Sharma R; Wechalekar K; Pennell DJ; Mohiaddin R
Heart; 2023 Apr; 109(10):748-755. PubMed ID: 36627181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
